

UNITED STATES DISTRICT COURT  
DISTRICT OF MASSACHUSETTS

IN RE: NEW ENGLAND COMPOUNDING  
PHARMACY, INC. PRODUCTS LIABILITY  
LITIGATION

MDL No. 2419

THIS DOCUMENT RELATES TO:

*Kennedy, et al. v. Unifirst, et al.*, No. 1:13-cv-13227; *Kennedy, et al. v. Advanced Pain & Anesthesia Consultants, et al.*, No. 1:14-cv-13689

*Musselwhite v. Unifirst, et al.*, No. 1:13-cv-13228; *Musselwhite v. Advanced Pain & Anesthesia Consultants, et al.*, No. 1:14-cv-13676

*Wynstock, et al. v. Ameridose, et al.*, No. 1:14-cv-12884

*Jeffries, et al. v. Ameridose, et al.*, No. 1:14-cv-12789

*Edwards v. Unifirst, et al.*, No. 1:13-cv-13209

Dkt. No. 1:13-md-02419-RWZ

**MEMORANDUM IN SUPPORT OF PLAINTIFFS' MOTION TO MODIFY THE  
THIRD AMENDED PROTECTIVE ORDER OF CONFIDENTIALITY**

The Plaintiffs' Steering Committee (PSC) moves to modify this Court's Third Amended Protective Order of Confidentiality (Dkt. # 814) governing the discovery conducted within this Court pursuant to Paragraph 23 of the Order.

1. On January 27, 2014, the Court entered an amended protective order to protect the confidentiality of non-public, confidential, and sensitive information that may be disclosed in connection with the MDL proceedings. (Dkt. #814.)

2. There are cases proceeding in state courts around the country. For example, there are at least four dozen cases pending in two state courts in Maryland. Many of these cases were never filed in, transferred to or moved to this Court. (*See id.* at 1.)
3. Many of these cases involve defendants that are not parties to this MDL; meaning, they were never a party within a case filed in, removed to, or transferred to the MDL. These defendants have nonetheless expressed the need for the MDL-related documents and depositions. They have not, however, signed the protective order. Even if they did, they cannot use the materials from the MDL in these never-within-the-MDL state court cases because of the current Protective Order's language.
4. This Court previously recognized the need for and importance of coordination between MDL and state counsel. (*See, e.g.*, Dkt # 82 (Procedural Order No. 2) at ¶ 8); Dkt. # 209 (Procedural Order No. 6) at 11 ("To the extent that there are NECC-related cases pending in state courts that are not a part of the MDL, but that fall within the subject matter definition of the MDL, this Court intends to coordinate with the state courts presiding over such cases, to the extent that such state courts are amenable.") The Court also noted that the discovery repository (*i.e.*, documents and depositions) was intended to benefit all plaintiffs across the country. (Dkt. # 209 (Procedural Order No. 6) at ¶ 5 on p. 15.) Those laudable goals are undermined by the current Protective Order language.
5. Specifically, the Order limits use of discovery material to this litigation. (*See* Dkt. 814 at ¶ 3A (limiting use to "the Litigation"); p. 1 (defining "the Litigation" as here only and not encompassing state court cases not brought within the MDL); ¶ 6A (does not contemplate state court cases that were never part of the MDL); ¶ 7C (limiting signatories to this Litigation and original transferor courts only).)

6. The PSC therefore requests that the Court modify the Protective Order (Dkt. # 814) or issue an Order that would permit use of the MDL materials, as permitted by the applicable rules of evidence and procedure, in any case. The goal is simply to assure the parties to these non-MDL cases can use the documents and depositions. They may be described accordingly as, cases concerning the September 2012 multistate outbreak of fungal meningitis and other infections involving patients who received or feared they had received contaminated preservative-free MPA steroid injections from the New England Compounding Center in Framingham, Massachusetts.
7. To that end, the PSC proposes the following changes to the Protective Order (Dkt. # 814), with added language in bold and underlined, and removed language in bold and stricken through:

- a. Edits on Page one:

This Order applies to all actions transferred to this Court by the Judicial Panel on Multidistrict Litigation pursuant to its order of February 12, 2013, any tag-along actions transferred to this Court by the Judicial Panel on Multidistrict Litigation pursuant to Rule 7.4 of the Rules of Procedure of that Panel, all related actions originally filed in this Court or transferred or removed to this Court, and any related actions subsequently filed in this Court, ~~and~~ any related actions subsequently filed in this Court otherwise transferred or removed to this Court, and any actions concerning the September 2012 multistate outbreak of fungal meningitis and other infections involving patients who received or feared they had received contaminated preservative-free MPA steroid injections from the New England Compounding Center in Framingham, Massachusetts, including cases filed in state courts

**that were never transferred or moved into this MDL, wherein one or more of the parties have agreed to be bound by this Order.**

b. Edit Paragraph 7, subparagraph C:

With respect to actions transferred to this Court pursuant to order of the Judicial Panel on Multidistrict Litigation, ~~and~~ subsequently remanded, **or otherwise proceeding elsewhere that concern the September 2012 multistate outbreak of fungal meningitis and other infections involving patients who received or feared they had received contaminated preservative-free MPA steroid injections from the New England Compounding Center in Framingham, Massachusetts, wherein one or more of the parties have agreed to be bound by this Order,** the ~~original transfer~~ court, including court personnel, jurors, mediators, special masters and alternate jurors, may receive Confidential Discovery Material.

c. Adding Paragraph 26

**Prior to receiving any materials covered by this Order, a signatory to it in a proceeding outside of the federal courts shall file it with that court and obtain a court order adopting it so that the materials remain protected and will be filed under seal or in accordance with that court's practices and procedures for handling confidential material.**

Dated: July 18, 2016

Respectfully submitted,



Mark P. Chalos

Mark P. Chalos  
Annika K. Martin  
LIEFF CABRASER HEIMANN & BERNSTEIN, LLP  
150 Fourth Avenue North, Suite 1650  
Nashville, TN 37219-2417  
Telephone: (615) 313.9000  
Facsimile: (615) 313.9965  
mchalos@lchb.com  
akmartin@lchb.com

*Federal/State Liaison and Pro Se Liaison*

Thomas M. Sobol  
Kristen Johnson  
HAGENS BERMAN SOBOL SHAPIRO LLP  
55 Cambridge Parkway, Suite 301  
Cambridge, MA 02142  
Telephone: (617) 482-3700  
Facsimile: (617) 482-3003  
tom@hbsslaw.com  
kristenj@hbsslaw.com

*Plaintiffs' Lead Counsel*

J. Gerard Stranch, IV  
Benjamin A. Gastel  
Anthony A. Orlandi  
BRANSETTER, STRANCH & JENNINGS PLLC  
227 Second Avenue North  
Nashville, TN 37201  
Telephone: (615) 254-8801  
Facsimile: (615) 255-5419  
gerards@branstetterlaw.com  
beng@branstetterlaw.com  
aorlandi@bsjfirm.com

Marc E. Lipton  
LIPTON LAW  
18930 W. 10 Mile Road  
Southfield, MI 48075  
Telephone: (248) 557-1688  
Facsimile: (248) 557-6344  
marc@liptonlawcenter.com

Kim Dougherty  
JANET, JENNER & SUGGS, LLC  
31 St. James Avenue, Suite 365  
Boston, MA 02116  
Telephone: (617) 933-1265  
kdougherty@myadvocates.com

Mark Zamora  
ZAMORA FIRM  
6 Concourse Way, 22nd Floor  
Atlanta, GA 30328  
Telephone: (404) 451-7781  
Facsimile: (404) 506-9223  
marc@markzamora.com

Patrick T. Fennell  
CRANDALL & KATT  
366 Elm Avenue, S.W.  
Roanoke, VA 24016  
Telephone: (540) 342-2000  
pfennel@crandalllaw.com

*Plaintiffs' Steering Committee*